(Q34119492)

31 July 2017

0 references

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis (English)

1 reference

31 July 2017

0 references

0 references

1 reference

3

Benjamin Djulbegovic

1 reference

31 July 2017

Gary H Lyman

1

1 reference

31 July 2017

Nicole M Kuderer

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

112

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

406-411

1 reference

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Update of the economic analyses of the use of the colony-stimulating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901036-7

10.1016/S0002-9343(02)01036-7

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference